Oric Pharmaceuticals presents Rinzimetostat preclinical data at AACR

ORIC Pharmaceuticals (ORIC) “announced the presentation of multiple poster presentations at the 2026 American Association for Cancer Research Annual Meeting highlighting the potential of rinzimetostat. or ORIC-944, a potent and selective allosteric inhibitor of PRC2 to treat prostate cancer. The posters can be found in the publication section of ORIC’s website here.” “Our research continues to show the therapeutic potential of PRC2 inhibition across the prostate cancer disease spectrum, by reducing tumor adaptability and sustaining the benefit derived from androgen-receptor targeted therapies,” said Lori Friedman, PhD, chief scientific officer. “Additionally, our preclinical studies reveal that targeting PRC2 via EED has potential advantages over targeting EZH2, which, together with the clinical data generated to date, furthers our conviction that rinzimetostat is a potential best-in-class PRC2 inhibitor.”